Whilst it was suggested, that T790M mutation is driven by EGFR-TKIs therapy, recently this is postulated, that this mutation is present at the very beginning in a rare clone of NSCLC cells even in EGFR-TKIs naive patient. This evidence concerns the gene EGFR and non-small cell lung carcinoma.